MYGN Q1 2019 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$454M

Q1 2019 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$217M+11.9% YoY

Gross Profit

$168M77.6% margin

Operating Income

$6M2.7% margin

Net Income

$7M3.2% margin

EPS (Diluted)

$0.09

QoQ Revenue Growth

-0.1%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$4M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$476M

Stockholders' Equity

$1.1B

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$217M	$194M	+11.9%
Gross Profit	$168M	$149M	+12.4%
Operating Income	$6M	$17M	-65.3%
Net Income	$7M	$11M	-39.5%

Revenue Segments

Diagnostics

$201M93%

All Other Segments

$16M7%

Geographic Segments

UNITED STATES

$204M94%

Non Us

$12M6%